Cited by 1,309Lung Cancer Treatments and MutationsLung Cancer Diagnosis and TreatmentLung Cancer Research Studies

The DOI matches its Crossref record; 35 of the 35 references it cites were found in a registry or an index.

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Open access

Garon, Edward B, Ciuleanu, Tudor-Eliade, Arrieta, Oscar, Prabhash, Kumar, Syrigos, Konstantinos N, Goksel, Tuncay, Park, Keunchil, Gorbunova, Vera, Kowalyszyn, Ruben Dario, Pikiel, Joanna, Czyzewicz, Grzegorz, Orlov, Sergey V, Lewanski, Conrad R, Thomas, Michael, Bidoli, Paolo, Dakhil, Shaker, Gans, Steven, Kim, Joo-Hang, Grigorescu, Alexandru, Karaseva, Nina, Reck, Martin, Cappuzzo, Federico, Alexandris, Ekaterine, Sashegyi, Andreas, Yurasov, Sergey, Pérol, Maurice·2014·The Lancet

DOI 10.1016/s0140-6736(14)60845-x

Open this paper in CoChat — free account

Abstract

Background Ramucirumab is a human IgG1 monoclonal antibody that targets the extracellular domain of VEGFR-2. We aimed to assess efficacy and safety of treatment with docetaxel plus ramucirumab or placebo as second-line treatment for patients with stage IV non-small-cell-lung cancer (NSCLC) after platinum-based therapy.Methods In this multicentre, double-blind, randomised phase 3 trial (REVEL), we enrolled patients with squamous or non-squamous NSCLC who had progressed during or after a first-line platinum-based chemotherapy regimen. Patients were randomly allocated (1:1) with a centralised, interactive voice-response system (stratified by sex, region, performance status, and previous maintenance therapy [yes vs no]) to receive docetaxel 75 mg/m(2) and either ramucirumab (10 mg/kg) or placebo on day 1 of a 21 day cycle until disease progression, unacceptable toxicity, withdrawal, or death. The primary endpoint was overall survival in all patients allocated to treatment. We assessed adverse events according to treatment received. This study is registered with ClinicalTrials.gov, number NCT01168973.Findings Between Dec 3, 2010, and Jan 24, 2013, we screened 1825 patients, of whom 1253 patients were randomly allocated to treatment. Median overall survival was 10·5 months (IQR 5·1-21·2) for 628 patients allocated ramucirumab plus docetaxel and 9·1 months (4·2-18·0) for 625 patients who received placebo plus docetaxel (hazard ratio 0·86, 95% CI 0·75-0·98; p=0·023). Median progression-free survival was 4·5 months (IQR 2·3-8·3) for the ramucirumab group compared with 3·0 months (1·4-6·9) for the control group (0·76, 0·68-0·86; p<0·0001). We noted treatment-emergent adverse events in 613 (98%) of 627 patients in the ramucirumab safety population and 594 (95%) of 618 patients in the control safety population. The most common grade 3 or worse adverse events were neutropenia (306 patients [49%] in the ramucirumab group vs 246 [40%] in the control group), febrile neutropenia (100 [16%] vs 62 [10%]), fatigue (88 [14%] vs 65 [10%]), leucopenia (86 [14%] vs 77 [12%]), and hypertension (35 [6%] vs 13 [2%]). The numbers of deaths from adverse events (31 [5%] vs 35 [6%]) and grade 3 or worse pulmonary haemorrhage (eight [1%] vs eight [1%]) did not differ between groups. Toxicities were manageable with appropriate dose reductions and supportive care.Interpretation Ramucirumab plus docetaxel improves survival as second-line treatment of patients with stage IV NSCLC.Funding Eli Lilly.

Integrity signals

Registry

Crossref · 10.1016/s0140-6736(14)60845-x

Cites

35 of 35 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Claims the paper makes

We couldn’t retrieve this paper’s full text, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

The hallmarks of cancer
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
EuroQol: a new facility for the measurement of health-related quality of life
(1990) · Health Policy · doi:10.1016/0168-8510(90)90421-9 · Cited by 15,736
New Guidelines to Evaluate the Response to Treatment in Solid Tumors
Therasse, P., Arbuck, S. G., Eisenhauer, E. A., Wanders, J., Kaplan, R. S., Rubinstein, L., Verweij, J., Van Glabbeke, M., van Oosterom, A. T., Christian, M. C., et al. (2000) · JNCI: Journal of the National Cancer Institute · doi:10.1093/jnci/92.3.205 · Cited by 15,660
Cancer statistics, 2012
Siegel, R., Naishadham, D., & Jemal, A. (2012) · CA: A Cancer Journal for Clinicians · doi:10.3322/caac.20138 · Cited by 10,679
Paclitaxel–Carboplatin Alone or with Bevacizumab for Non–Small-Cell Lung Cancer
Sandler, A., Gray, R., Perry, M. C., Brahmer, J., Schiller, J. H., Dowlati, A., Lilenbaum, R., & Johnson, D. H. (2006) · New England Journal of Medicine · doi:10.1056/nejmoa061884 · Cited by 5,761
Erlotinib in Previously Treated Non–Small-Cell Lung Cancer
Shepherd, F. A., Rodrigues Pereira, J., Ciuleanu, T., Tan, E. H., Hirsh, V., Thongprasert, S., Campos, D., Maoleekoonpiroj, S., Smylie, M., Martins, R., et al. (2005) · New England Journal of Medicine · doi:10.1056/nejmoa050753 · Cited by 5,419
Self-citation
Randomized Phase III Trial of Pemetrexed Versus Docetaxel in Patients With Non–Small-Cell Lung Cancer Previously Treated With Chemotherapy
Hanna, N., Shepherd, F. A., Fossella, F. V., Pereira, J. R., De Marinis, F., von Pawel, J., Gatzemeier, U., Tsao, T. C. Y., Pless, M., Muller, T., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.08.163 · Cited by 2,426
Prospective Randomized Trial of Docetaxel Versus Best Supportive Care in Patients With Non–Small-Cell Lung Cancer Previously Treated With Platinum-Based Chemotherapy
Shepherd, F. A., Dancey, J. E., Ramlau, R., Mattson, K. V., Gralla, R. J., O’Rourke, M. A., Levitan, N. I., Gressot, L., Vincent, M. D., Burkes, R. L., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.10.2095 · Cited by 2,178
Ramucirumab monotherapy for previously treated advanced gastric or gastro-oesophageal junction adenocarcinoma (REGARD): an international, randomised, multicentre, placebo-controlled, phase 3 trial.
Fuchs, C., Tomášek, J., Cho, J., Dumitru, F., Passalacqua, R., Goswami, C., Safran, H., dos Santos, L. D., Aprile, G., Ferry, D., et al. (2014) · The Lancet · doi:10.1016/s0140-6736(13)61719-5 · Cited by 2,031
Self-citation
Randomized Phase II Trial Comparing Bevacizumab Plus Carboplatin and Paclitaxel With Carboplatin and Paclitaxel Alone in Previously Untreated Locally Advanced or Metastatic Non-Small-Cell Lung Cancer
Johnson, D. H., Fehrenbacher, L., Novotny, W. F., Herbst, R. S., Nemunaitis, J. J., Jablons, D. M., Langer, C. J., DeVore, R. F., Gaudreault, J., Damico, L. A., et al. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.11.022 · Cited by 1,948

Show all 35 references

Research works printed but not linked: 1

Wilke, 2014, J Clin Oncol, 32

Sorted by citations

Items 701–800 of 1,001

Adjusting the dose of traditional drugs combined with immunotherapy: reshaping the immune microenvironment in lung cancer
Wang, L., Du, C., Jiang, B., Chen, L., & Wang, Z. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1256740 · Cited by 8
Survival Outcomes After Double-Lung Transplantation for Refractory Lung-Limited Cancers and Incidence of Post-Transplant Lung Cancer
Lee, J., Chuchuca, M. J. A., Yu, J., Chung, L. I., Bharat, A., & Chae, Y. K. (2023) · Annals of Transplantation · doi:10.12659/aot.941301 · Cited by 8
Enhancing the Budget Impact Model for Institutional Use: A Tool with Practical Applications for the Hospital Oncology Pharmacy
Hess, L. M., Cinfio, F. N., Wetmore, S., Churchill, C., Fausel, C. A., Ale-Ali, A., Gelwicks, S., Bly, C. A., Perk, S., & Klein, R. W. (2016) · Hospital Pharmacy · doi:10.1310/hpj5106-452 · Cited by 8
Bevacizumab for ramucirumab refractory malignant pleural effusion in non-small cell lung cancer: a case report and review of the literature
Mori, R., Fujimoto, D., Ito, M., & Tomii, K. (2017) · Oncotarget · doi:10.18632/oncotarget.17952 · Cited by 8
Population-level effect of molecular testing and targeted therapy in patients with advanced pulmonary adenocarcinoma: a prospective cohort study
Schwegler, C., Kaufmann, D., Pfeiffer, D., Aebi, S. P., Diebold, J., & Gautschi, O. P. (2017) · Archiv für Pathologische Anatomie und Physiologie und für Klinische Medicin · doi:10.1007/s00428-017-2268-y · Cited by 8
Phase II Study of S-1 and Paclitaxel Combination Therapy in Patients with Previously Treated Non-Small Cell Lung Cancer
Chihara, Y., Yoshimura, A., Date, K., Takemura, Y., Tamiya, N., Kohno, Y., Imabayashi, T., Takeuchi, M., Kaneko, Y., Yamada, T., et al. (2019) · The Oncologist · doi:10.1634/theoncologist.2019-0290 · Cited by 8
Synergies of Targeting Angiogenesis and Immune Checkpoints in Cancer: From Mechanism to Clinical Applications
Zhou, S., & Zhang, H. (2020) · Anti-Cancer Agents in Medicinal Chemistry · doi:10.2174/1871520620666200207091653 · Cited by 7
Interstitial lung disease induced by docetaxel and ramucirumab chemotherapy after nivolumab treatment
Okeya, K., Kawagishi, Y., Yamoto, M., Shimizu, M., Imizuda, T., & Tsuji, H. (2020) · Respirology Case Reports · doi:10.1002/rcr2.564 · Cited by 8
Immune checkpoint inhibitors versus second line chemotherapy for patients with lung cancer refractory to first line chemotherapy
Lefèbvre, C., Martin, E., Hendriks, L. E. L., Veillon, R., Puisset, F., Mezquita, L., Ferrara, R., Sabatier, M., Filleron, T., Dingemans, A. C., et al. (2020) · Respiratory Medicine and Research · doi:10.1016/j.resmer.2020.100788 · Cited by 8
Safety and Efficacy of Low-Dosage Apatinib Monotherapy in Advanced Lung Squamous-Cell Carcinoma: A Prospective Cohort Study
Geng, Q., Shen, H., Zhu, W., Lu, Y., Wang, M., Jiang, H., & Li, D. (2020) · OncoTargets and Therapy · doi:10.2147/ott.s277532 · Cited by 8
A Review of Monoclonal Antibody-Based Treatments in Non-small Cell Lung Cancer
Panahi, Y., Mohammadzadeh, A. H., Behnam, B., Orafai, H. M., Jamialahmadi, T., & Sahebkar, A. (2021) · Advances in experimental medicine and biology · doi:10.1007/978-3-030-55035-6_3 · Cited by 8
Risk of hypertension with anti-VEGF monoclonal antibodies in cancer patients: a systematic review and meta-analysis of 105 phase II/III randomized controlled trials
Yin, G., & Zhao, L. (2021) · Journal of Chemotherapy · doi:10.1080/1120009x.2021.1947022 · Cited by 9
Ramucirumab-related osteonecrosis of the jaw
Singh, A., Pischek, A. M., Randazzo, J. R., Huryn, J. M., Estilo, C. L., Preeshagul, I. R., & Yom, S. K. (2021) · Oral Oncology · doi:10.1016/j.oraloncology.2021.105660 · Cited by 8
When to add anti-angiogenesis drugs to EGFR-mutated metastatic non–small cell lung cancer patients: a real-world study from Taiwan
Chen, C., Wang, S.-T., Liao, W.-C., Chen, C., Tu, C., Chen, H.-J., Hsia, T., & Cheng, W. (2022) · BMC Cancer · doi:10.1186/s12885-022-09672-4 · Cited by 8
Anti-Angiogenic Therapy in ALK Rearranged Non-Small Cell Lung Cancer (NSCLC)
Tan, A. C., & Pavlakis, N. (2022) · International Journal of Molecular Sciences · doi:10.3390/ijms23168863 · Cited by 8
Malignant neoplasm of the bronchi and lung: Russian clinical guidelines
Лактионов, К. К., Артамонова, Е. В., Borisova, T. N., Breder, V. V., Маркович, Б. Ю., Vladimirova, L. Y., Волков, Н. М., Ергнян, С. М., Жабина, А. С., Kononets, P. V., et al. (2022) · Journal of Modern Oncology · doi:10.26442/18151434.2022.3.201848 · Cited by 9
Bevacizumab versus Ramucirumab in EGFR-Mutated Metastatic Non-Small-Cell Lung Cancer Patients: A Real-World Observational Study
Cheng, W., Shen, Y., Chen, C., Liao, W.-C., Chen, C., Chen, H.-J., Tu, C., & Hsia, T. (2023) · Cancers · doi:10.3390/cancers15030642 · Cited by 8
Sequencing strategies with ramucirumab and docetaxel following prior treatments for advanced non-small cell lung cancer: a multicenter retrospective cohort study
Tanizaki, S., Matsumoto, K., Tamiya, A., Taniguchi, Y., Matsuda, Y., Uchida, J., Ueno, K., Kawachi, H., Tamiya, M., Yanase, T., et al. (2023) · European Journal of Clinical Pharmacology · doi:10.1007/s00228-023-03452-0 · Cited by 8
Emerging treatments and combinations in the management of NSCLC: clinical potential of nintedanib
Reck, M., & Mellemgaard, A. (2015) · Biologics · doi:10.2147/btt.s57356 · Cited by 8
Self-citation
Present standards and future perspectives in the treatment of metastatic non-small cell lung cancer
Zimmermann, S., & Peters, S. (2015) · Cancer and Metastasis Reviews · doi:10.1007/s10555-015-9560-6 · Cited by 8
The comparison of outcomes from tyrosine kinase inhibitor monotherapy in second- or third-line for advanced non-small-cell lung cancer patients with wild-type or unknown EGFR status
Bronte, G., Franchina, T., Alù, M., Sortino, G., Celesia, C., Passiglia, F., Savio, G., Laudani, A., Russo, A., Picone, A., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.8130 · Cited by 8
Hematopoietic growth factors in lung cancer
Genova, C., Rijavec, E., & Grossi, F. (2016) · Current Opinion in Oncology · doi:10.1097/cco.0000000000000268 · Cited by 8
A phase 1 study of ramucirumab in Japanese patients with advanced solid tumors
Nokihara, H., Yamamoto, N., Yamada, Y., Honda, K., Asahina, H., Tamura, Y., Hozak, R. R., Gao, L., Suzukawa, K., Enatsu, S., et al. (2017) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyx008 · Cited by 8
Bayesian Phase II optimization for time-to-event data based on historical information
Bertsche, A., Fleischer, F., Beyersmann, J., & Nehmiz, G. (2017) · Statistical Methods in Medical Research · doi:10.1177/0962280217747310 · Cited by 8
Japanese subgroup analysis of a phase III study of S-1 versus docetaxel in non-small cell lung cancer patients after platinum-based treatment: EAST-LC
Sugawara, S., Nakagawa, K., Yamamoto, N., Nokihara, H., Ohe, Y., Nishio, M., Takahashi, T., Goto, K., Maemondo, M., Ichinose, Y., et al. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01396-z · Cited by 8
Recent treatment strategy for advanced squamous cell carcinoma of the lung in Japan
Senoo, S., Ninomiya, K., Hotta, K., & Kiura, K. (2019) · International Journal of Clinical Oncology · doi:10.1007/s10147-019-01424-y · Cited by 8
The Impact of EGFR Mutation Status and Brain Metastasis for Non-Small Cell Lung Cancer Treated with Ramucirumab plus Docetaxel
Furuya, N., Ito, K., Sakaguchi, T., Hida, N., Kakinuma, K., Morikawa, K., Inoue, T., Komase, Y., Hataji, O., & Mineshita, M. (2020) · Oncology · doi:10.1159/000507050 · Cited by 8
Pharmacotherapy of Anal Cancer
Rogers, J. E., & Eng, C. (2017) · Drugs · doi:10.1007/s40265-017-0792-3 · Cited by 8
Second-Line Treatment Options in Non–Small-Cell Lung Cancer: Report From an International Experts Panel Meeting of the Italian Association of Thoracic Oncology
Gridelli, C., Baas, P., Barlési, F., Ciardiello, F., Crinò, L., Felip, E., Gadgeel, S. M., Papadimitrakopoulou, V., Paz-Ares, L. G., Planchard, D., et al. (2017) · Clinical Lung Cancer · doi:10.1016/j.cllc.2017.12.010 · Cited by 8
Heterogeneity and therapeutic implications of cancer-associated fibroblasts in lung cancer: Recent advances and future perspectives
Yang, C., Liu, W., Powell, C. A., & Wang, Q. (2024) · Chinese Medical Journal - Pulmonary and Critical Care Medicine · doi:10.1016/j.pccm.2024.08.009 · Cited by 7
Prognostic factors in non-small cell lung cancer patients who are recommended to receive single-agent chemotherapy (docetaxel or pemetrexed) as a second- or third-line chemotherapy: in the era of oncogenic drivers and molecular-targeted agents
Shukuya, T., Ko, R., Mori, K. P., Kato, M., Yagishita, S., Kanemaru, R., Honma, Y., Shibayama, R., Koyama, R., Shimada, N., et al. (2015) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-015-2843-3 · Cited by 7
Value of chemotherapy post immunotherapy in stage IV non-small cell lung cancer (NSCLC)
Assi, H. I., Zerdan, M. B., Hodroj, M. H., Khoury, M., Naji, N. S., Amhaz, G., Zeidane, R. A., & Karak, F. E. (2023) · Oncotarget · doi:10.18632/oncotarget.28444 · Cited by 7
Efficacy of Nanoparticle Albumin-Bound Paclitaxel (nab-PTX) Monotherapy Can Be Improved after Treatment with Immune Checkpoint Inhibitor in Patients with Non-Small Cell Lung Cancer: Long-Term Follow-Up and Updated Analysis of Two Previous Prospective Clinical Studies
Nakashima, K., Umeda, Y., Demura, Y., Sonoda, T., Tada, T., Yamaguchi, M., Anzai, M., Kadowaki, M., Oi, M., Honjo, C., et al. (2024) · Oncology · doi:10.1159/000535994 · Cited by 7
Updates in pharmacotherapy for non-small cell lung cancer: a focus on emerging tubulin inhibitors
Nardin, S., Sacco, G., D’Amato, A. L., Barcellini, L., Rovere, M., Santamaria, S., Marconi, S., Coco, S., & Genova, C. (2024) · Expert Opinion on Pharmacotherapy · doi:10.1080/14656566.2024.2369196 · Cited by 7
Safety and pharmacokinetics of ramucirumab in combination with docetaxel in Japanese patients with locally advanced or metastatic breast cancer: a Phase Ib study
Masuda, N., Iwata, H., Aogi, K., Xu, Y., Ibrahim, A. B., Gao, L., Dalal, R. P., Yoshikawa, R., & Sasaki, Y. (2016) · Japanese Journal of Clinical Oncology · doi:10.1093/jjco/hyw127 · Cited by 7
Systemic effects of angiogenesis inhibition alter pharmacokinetics and intratumoral delivery of nab-paclitaxel
Steins, A., Ebbing, E. A., Pistorius, M. C. M., Waasdorp, C., Krishnadath, K. K., Medema, J. P., Wilmink, J. W., Mathôt, R. A. A., Bijlsma, M. F., & van Laarhoven, H. W. M. (2017) · Drug Delivery · doi:10.1080/10717544.2017.1406559 · Cited by 7
A case of ramucirumab-related gastrointestinal perforation in gastric cancer with small bowel metastasis
Urakawa, S., Sakai, D., Miyazaki, Y., Kudo, T., Katou, A., Inagaki, C., Tanaka, K., Makino, T., Takahashi, T., Kurokawa, Y., et al. (2017) · Surgical Case Reports · doi:10.1186/s40792-017-0399-7 · Cited by 7
Clinical utility of ramucirumab in non-small-cell lung cancer
Uprety, D. (2019) · Biologics · doi:10.2147/btt.s175034 · Cited by 7
A randomized phase II trial evaluating the addition of low dose, short course sunitinib to docetaxel in advanced solid tumours
Ang, Y. L. E., Ho, G. F., Soo, R. A., Sundar, R., Tan, S. H., Yong, W. P., Ow, S. G. W., Lim, J. S. J., Chong, W. Q., Phyu, P. S., et al. (2020) · BMC Cancer · doi:10.1186/s12885-020-07616-4 · Cited by 7
Second-line Afatinib or Chemotherapy Following Immunochemotherapy for the Treatment of Metastatic, Squamous Cell Carcinoma of the Lung: Real-world Effectiveness and Safety From a Multisite Retrospective Chart Review in the USA
Kim, E. S., Kish, J. K., Cseh, A., Moehring, B., Tang, W., Terlizzi, E., & Subramanian, J. (2021) · Clinical Lung Cancer · doi:10.1016/j.cllc.2021.02.006 · Cited by 7
Clinical development and evaluation of a VEGF-D assay in plasma from patients with metastatic colorectal cancer in the RAISE study
Taniguchi, H., Yoshino, T., Yamaguchi, K., Yamazaki, K., Nixon, A. B., Tabernero, J. M., Cutsem, E. V., Robling, K., Abada, P., Hozak, R. R., et al. (2021) · Current Medical Research and Opinion · doi:10.1080/03007995.2021.1940908 · Cited by 7
The safety and efficacy of erlotinib and ramucirumab combination in EGFR-mutant non-small-cell lung cancer
Boussageon, M., Swalduz, A., & Pérol, M. (2021) · Expert Review of Anticancer Therapy · doi:10.1080/14737140.2021.1958679 · Cited by 7
Antiangiogenic drugs: Chemosensitizers for combination cancer therapy
Donnini, S., Filippelli, A., Ciccone, V., Spini, A., Ristori, E., Ziche, M., & Morbidelli, L. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-90190-1.00008-1 · Cited by 7
Impact of treatment line on risks and benefits of immune checkpoint inhibitor in patients with advanced non-small cell lung cancer and interstitial lung disease: a systematic review and meta-analysis of cohort studies
Matsumoto, K., Shiroyama, T., Kuge, T., Miyake, K., Yamamoto, Y., Yoneda, M., Yamamoto, M., Naito, Y., Suga, Y., Fukushima, K., et al. (2022) · Translational Lung Cancer Research · doi:10.21037/tlcr-22-162 · Cited by 7
What’s the latest with investigational drugs for soft tissue sarcoma?
Cojocaru, E., Napolitano, A., Fisher, C., Huang, P. H., Jones, R. L., & Thway, K. (2022) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2022.2152324 · Cited by 7
Efficacy and safety of nintedanib and docetaxel in patients with previously treated lung non-squamous non-small cell lung cancer: a multicenter retrospective real-world analysis
Ljubičić, L., Janžič, U., Unk, M., Terglav, A. S., Mohorčič, K., Seiwerth, F., Bitar, L., Badovinac, S., Pleština, S., Koršić, M., et al. (2023) · Radiology and Oncology · doi:10.2478/raon-2023-0040 · Cited by 7
Rationale for Targeting the ErbB Family of Receptors in Patients with Advanced Squamous Cell Carcinoma of the Lung
Hall, P. E., Spicer, J. F., & Popat, S. (2015) · Future Oncology · doi:10.2217/fon.15.110 · Cited by 7
Immunotherapy for Non-Small-Cell Lung Cancer: The Past 10 Years
Vansteenkiste, J., Craps, J., Brucker, N. D., & Wauters, I. (2015) · Future Oncology · doi:10.2217/fon.15.116 · Cited by 7
An overview of angiogenesis inhibitors in Phase II studies for non-small-cell lung cancer
Pilotto, S., Novello, S., Peretti, U., Kinspergher, S., Ciuffreda, L., Milella, M., Carbognin, L., Vavalà, T., Ferrara, R., Caccese, M., et al. (2015) · Expert Opinion on Investigational Drugs · doi:10.1517/13543784.2015.1056341 · Cited by 7
Mechanisms that influence tumour response to VEGF-pathway inhibitors
Smith, N. R., Wedge, S. R., Pommier, A., & Barry, S. T. (2014) · Biochemical Society Transactions · doi:10.1042/bst20140261 · Cited by 7
Clinical pharmacokinetics and pharmacodynamics of ramucirumab in the treatment of colorectal cancer
Gambardella, V., Tarazona, N., Cejalvo, J. M., Roselló, S., & Cervantes, A. M. R. (2016) · Expert Opinion on Drug Metabolism & Toxicology · doi:10.1517/17425255.2016.1156084 · Cited by 7
Profiling of Vascular Endothelial Growth Factor Receptor Heterogeneity Identifies Protein Expression-defined Subclasses of Human Non-small Cell Lung Carcinoma.
Holzer, T. R., Fulford, A. D., Reising, L. O., Nedderman, D. M., Zhang, X., Benjamin, L. E., Schade, A. E., & Nasir, A. (2016) · PubMed · Cited by 7
Investigational therapies for squamous cell lung cancer: from animal studies to phase II trials
Shum, E., Wang, F., Kim, S., Perez-Soler, R., & Cheng, H. (2017) · Expert Opinion on Investigational Drugs · doi:10.1080/13543784.2017.1302425 · Cited by 7
Apatinib for heavily treated patients with non-small cell lung cancer: Report of a case series and literature review
Yang, D., Dai, R., Zhang, Q., & Fang, P. (2017) · Saudi Journal of Biological Sciences · doi:10.1016/j.sjbs.2017.12.011 · Cited by 7
Afatinib vs erlotinib for second-line treatment of Chinese patients with advanced squamous cell carcinoma of the lung
Lü, S., Li, W., Zhou, C., Hu, C., Qin, S., Cheng, G., Feng, J., Wang, J., Cseh, A., Peil, B., et al. (2018) · OncoTargets and Therapy · doi:10.2147/ott.s161506 · Cited by 8
KEYNOTE-407: changing the way we treat stage IV squamous non-small cell lung cancer
Pacheco, J. M. (2020) · Translational Lung Cancer Research · doi:10.21037/tlcr.2020.01.12 · Cited by 7
Angiogenesis and Its Role in the Tumour Microenvironment: A Target for Cancer Therapy
Frentzas, S., Lum, C., & Chen, T. (2020) · IntechOpen eBooks · doi:10.5772/intechopen.89667 · Cited by 7
The Anti-Angiogenic Effects of Anti-Human Immunodeficiency Virus Drugs
Barillari, G. (2020) · Frontiers in Oncology · doi:10.3389/fonc.2020.00806 · Cited by 7
Efficacy and safety of ramucirumab plus docetaxel in older patients with advanced non-small cell lung cancer: A multicenter retrospective cohort study
Matsumoto, K., Tamiya, A., Inagaki, Y., Taniguchi, Y., Matsuda, Y., Kawachi, H., Tamiya, M., Tanizaki, S., Uchida, J., Ueno, K., et al. (2021) · Journal of Geriatric Oncology · doi:10.1016/j.jgo.2021.09.004 · Cited by 7
Real-World Treatment Sequences and Outcomes Among Patients With Non-Small Cell Lung Cancer (RESOUNDS) in the United States: Study Protocol
Hess, L. M., Kern, D. M., Carter, G. C., Winfree, K. B., Wang, L., Sontag, A., & Oton, A. B. (2017) · JMIR Research Protocols · doi:10.2196/resprot.7750 · Cited by 7
Efficacy and Safety of Addition of Anti-PD1 to Chemotherapy in Treatment of Non-Small Cell Lung Cancer
Ru, C., & Zhuang, Y.-B. (2019) · Combinatorial Chemistry & High Throughput Screening · doi:10.2174/1386207322666190125150921 · Cited by 7
The crosstalk between lung cancer and the bone marrow niche fuels emergency myelopoiesis
Calderon-Espinosa, E., Ridder, K. D., Benoot, T., Jansen, Y. J. L., Vanhonacker, D., Heestermans, R., Becker, A. D., Riet, I. V., Decoster, L., & Goyvaerts, C. (2024) · Frontiers in Immunology · doi:10.3389/fimmu.2024.1397469 · Cited by 6
Unlocking the Molecular Targets in Non-Small-Cell Lung Cancer and a Nanomedicine-Based Remedy
Sarma, K., Akhter, M. H., Alalmaie, A., Ahmad, I., Ansari, M. N., Khalilullah, H., Farhana, S. A., Hussain, S. M., & Aljadaan, A. M. (2025) · Critical Reviews in Therapeutic Drug Carrier Systems · doi:10.1615/critrevtherdrugcarriersyst.2024053289 · Cited by 6
Comparative Efficacy and Safety of Anti-PD-1/PD-L1 Immune Checkpoint Inhibitors for Refractory or Relapsed Advanced Non-Small-Cell Lung Cancer—A Systematic Review and Network Meta-Analysis
Andō, K., Manabe, R., Kishino, Y., Kusumoto, S., Yamaoka, T., Tanaka, A., Ohmori, T., Ohnishi, T., & Sagara, H. (2020) · Cancers · doi:10.3390/cancers13010052 · Cited by 6
The effects of tislelizumab treatment on the health‐related quality of life of patients with advanced non‐small cell lung cancer
Huang, D., Zhou, C., Barnes, G., Ma, Y., Li, S., Zhan, L., & Tang, B. (2023) · Cancer Medicine · doi:10.1002/cam4.6361 · Cited by 6
Monoclonal Antibody Development for Cancer Treatment Using the Phage Display Library Platform
Zhang, T., & Wang, Z. (2024) · Biologics · doi:10.3390/biologics4010005 · Cited by 6
Towards Targeting Endothelial Rap1B to Overcome Vascular Immunosuppression in Cancer
Nakhchi, B. G., Kosuru, R., & Chrzanowska‐Wodnicka, M. (2024) · International Journal of Molecular Sciences · doi:10.3390/ijms25189853 · Cited by 7
Evaluation of Anti-Angiogenic Therapy Combined with Immunotherapy and Chemotherapy as a Strategy to Treat Locally Advanced and Metastatic Non-Small-Cell Lung Cancer
Abdallah, M., Voland, R. P., DeCamp, M. M., Flíckinger, J. C., Pacioles, T. O., Jamil, M. O., Silbermins, D., Shenouda, M. N., Valsecchi, M. E., Bir, A., et al. (2024) · Cancers · doi:10.3390/cancers16244207 · Cited by 7
Locally Advanced Non-Small Cell Lung Cancer: Optimal Chemotherapeutic Agents and Duration
Mamdani, H. M., Jalal, S. I., & Hanna, N. H. (2015) · Current Treatment Options in Oncology · doi:10.1007/s11864-015-0364-2 · Cited by 6
W‘ALK’ Into the Next Stage
Toyokawa, G., Seto, T., Takenoyama, M., & Ichinose, Y. (2016) · Clinical Lung Cancer · doi:10.1016/j.cllc.2016.10.005 · Cited by 6
Treatment rationale and design of the RAMNITA study
Tanimura, K., Uchino, J., Tamiya, N., Kaneko, Y., Yamada, T., Yoshimura, K., & Takayama, K. (2018) · Medicine · doi:10.1097/md.0000000000011084 · Cited by 6
Comprehensive expressional analysis of chemosensitivity‐related markers in large cell neuroendocrine carcinoma of the lung
Ohtaki, Y., Kaira, K., Yajima, T., Erkhem‐Ochir, B., Kawashima, O., Kamiyoshihara, M., Igai, H., Onozato, R., Ibe, T., Kosaka, T., et al. (2021) · Thoracic Cancer · doi:10.1111/1759-7714.14102 · Cited by 5
RELAY, ramucirumab plus erlotinib versus placebo plus erlotinib in untreated EGFR-mutated metastatic non-small cell lung cancer: exposure–response relationship
Nakagawa, K., Garon, E. B., Gao, L., Callies, S., Zimmermann, A. H., Walgren, R. A., Visseren‐Grul, C., & Reck, M. (2022) · Cancer Chemotherapy and Pharmacology · doi:10.1007/s00280-022-04447-x · Cited by 6
Self-citation
The benefit of anti-angiogenic therapy in EGFR exon 21 L858R mutant non-small cell lung cancer patients: a retrospective study
You, L., Zheng, X., Deng, D., Pan, H., & Han, W. (2022) · Scientific Reports · doi:10.1038/s41598-022-18889-z · Cited by 6
High tumor burden in non-small-cell lung cancer: A review of the literature
Cabezón‐Gutiérrez, L., Sereno, M., Cervera, R., Mielgo-Rubio, X., & Higuera, O. (2022) · Journal of Clinical and Translational Research · doi:10.18053/jctres.08.202205.008 · Cited by 6
Optimizing the Dosing Regimen of Cetuximab and Ramucirumab Using the Model‐Informed Drug Development Paradigm
Ni, L., Khan, A. Z., Long, A. J., Gao, L., Toms, N., González-Gugel, E., Holsmer‐Brand, S., Lin, Y. Q., Abada, P., Dickin, S., et al. (2023) · Clinical Pharmacology & Therapeutics · doi:10.1002/cpt.2919 · Cited by 6
Regulation of VEGFR2 and AKT Signaling by Musashi-2 in Lung Cancer
Bychkov, I., Topchu, I., Makhov, P. B., Kudinov, A. E., Patel, J. D., & Boumber, Y. (2023) · Cancers · doi:10.3390/cancers15092529 · Cited by 6
Real-World Data About Treatment Outcomes for Patients with EGFR-Mutated NSCLC Resistance to Osimertinib and Platinum-Based Chemotherapy
Hayashi, H., Nishio, M., Takahashi, M., Tsuchiya, H., & Kasahara‐Kiritani, M. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02616-9 · Cited by 6
Current and Emerging Treatment Options for Patients with Metastatic EGFR-Mutated Non-small Cell Lung Cancer After Progression on Osimertinib and Platinum-Based Chemotherapy: A Podcast Discussion
Patel, S. P., & Patel, J. D. (2023) · Advances in Therapy · doi:10.1007/s12325-023-02680-1 · Cited by 6
Prospective Observational Study of Ramucirumab Plus Docetaxel After Combined Chemoimmunotherapy in Patients With Non-Small-Cell Lung Cancer
Katayama, Y., Yamada, T., Sawada, R., Kawachi, H., Morimoto, K., Watanabe, S., Watanabe, K., Takeda, T., Chihara, Y., Shiotsu, S., et al. (2024) · The Oncologist · doi:10.1093/oncolo/oyae001 · Cited by 6
Risk of Hematological Toxicities in Patients with Solid Tumors Treated with Ramucirumab: A Meta-Analysis
Abdel-Rahman, O. M., & Elhalawani, H. M. (2015) · Future Oncology · doi:10.2217/fon.15.178 · Cited by 6
Increased risk of severe infections in cancer patients treated with vascular endothelial growth factor receptor tyrosine kinase inhibitors: a meta-analysis
Zhong, D., Ma, Q., Gu, L., Ren, Y., Zeng, L.-L., & Gong, T. (2015) · OncoTargets and Therapy · doi:10.2147/ott.s87298 · Cited by 7
A REVELation in non-small-cell lung cancer treatment?
Mok, T. S. K., & Loong, H. H.-F. (2014) · The Lancet · doi:10.1016/s0140-6736(14)60895-3 · Cited by 6
Ramucirumab for the treatment of gastroesophageal cancers
Shimodaira, Y., Elimova, E. C., Wadhwa, R., Shiozaki, H., Charalampakis, N., Planjery, V., Blum, M. A., Esteralla, J. S., Rogers, J. E., Song, S., et al. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2015.1040390 · Cited by 6
Clinical experience with ramucirumab: outcomes in breast cancer
Coyne, G. O., & Burotto, M. (2014) · Expert Opinion on Biological Therapy · doi:10.1517/14712598.2014.939069 · Cited by 6
[Recombinant Human Endostatin in the Treatment of Advanced Lung Squamous Cell Carcinoma].
Xing, P., Hao, X., Hu, X., Wang, Y., & Li, J. (2016) · Europe PMC (PubMed Central) · doi:10.3779/j.issn.1009-3419.2016.10.06 · Cited by 6
Adverse events risk associated with anti-VEGFR agents in the treatment of advanced nonsmall-cell lung cancer
Gu, B., Gao, W., Chu, H., Gao, J., Fu, Z., Ding, H., Lv, J., & Wu, Q. (2016) · Medicine · doi:10.1097/md.0000000000003752 · Cited by 6
Indian consensus statement for treatment of advanced non small cell lung cancer: First line, maintenance, and second line
Indian Cooperative Oncology Network (ICON) (2017) · Indian Journal of Cancer · doi:10.4103/ijc.ijc_136_17 · Cited by 6
Phase II study of ramucirumab and docetaxel for previously treated non‐small cell lung cancer patients with malignant pleural effusion: Protocol of PLEURAM study
Takemoto, S., Fukuda, M., Yamaguchi, H., Ikeda, T., Akagi, K., Tomono, H., Umeyama, Y., Dotsu, Y., Taniguchi, H., Gyotoku, H., et al. (2019) · Thoracic Cancer · doi:10.1111/1759-7714.13279 · Cited by 6
A multi‐targeted treatment approach to cancer cachexia: Auckland's Cancer Cachexia evaluating Resistance Training (ACCeRT) trial
Rogers, E., Sasidharan, R., Sequeira, G. M., Wood, M. R., Bird, S. P., Keogh, J., Arroll, B., STEWART, J. M., & MacLeod, R. (2020) · JCSM Rapid Communications · doi:10.1002/rco2.10 · Cited by 7
Thyroid Dysfunction Related to the Antiangiogenic VEGFR2-Binding Monoclonal Antibody Ramucirumab: A Series of 14 Cases and a Descriptive Study
Dote, S., Yamaguchi, D., Hira, D., Noda, S., Kobayashi, Y., & Terada, T. (2020) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.b19-01071 · Cited by 6
The optimal immune checkpoint inhibitors combined with chemotherapy for advanced non-small-cell lung cancer: a systematic review and meta-analysis
Yang, Y., Luo, H., Zheng, X., & Ge, H. (2020) · Clinical & Translational Oncology · doi:10.1007/s12094-020-02502-8 · Cited by 7
Nacimiento de la quimioterapia
Camacho, L. H. (2021) · Medicina · doi:10.56050/01205498.1562 · Cited by 4
Bevacizumab with Single-agent Chemotherapy in Previously Treated Non-squamous Non-small-cell Lung Cancer: Phase II Study
Yamaguchi, K., Masuda, T., Fujitaka, K., Miwata, K., Sakamoto, S., Horimasu, Y., Hamai, K., Miyamoto, S., Nakashima, T., Okamoto, Y., et al. (2018) · In Vivo · doi:10.21873/invivo.11358 · Cited by 6
Development of treatment options for Chinese patients with advanced squamous cell lung cancer: focus on afatinib
Lü, S. (2019) · OncoTargets and Therapy · doi:10.2147/ott.s188296 · Cited by 6
US FDA oncology drug approvals in 2014
Wolford, J. E., & Tewari, K. S. (2015) · Future Oncology · doi:10.2217/fon.15.106 · Cited by 6
S-1-Based Regimens for Locally Advanced/Metastatic Non-Small-Cell Lung Cancer: A Meta-Analysis
Abdel-Rahman, O. M., & Elhalawani, H. M. (2016) · Future Oncology · doi:10.2217/fon.15.338 · Cited by 6
A Critical Review on Ramucirumab in the Treatment of Advanced Urothelial Cancer
Vlachostergios, P. J., Lee, A., Thomas, C., Walsh, R., & Tagawa, S. T. (2017) · Future Oncology · doi:10.2217/fon-2017-0473 · Cited by 6
Epidermal growth factor tyrosine kinase inhibitor therapy inferior to second-line chemotherapy in EGFR wild-type non-small cell lung cancer patients: results of French nationwide observational study
Lisberg, A. E., & Garon, E. B. (2017) · Translational Lung Cancer Research · doi:10.21037/tlcr.2017.10.16 · Cited by 6
Self-citation
TROP2-Directed Antibody-Drug Conjugates in Advanced Non–Small Cell Lung Cancer: A Fading Hope?
Pérol, M. (2024) · Journal of Clinical Oncology · doi:10.1200/jco.24.01043 · Cited by 6

A Randomized, Double-Blind, Phase III Study of Docetaxel and Ramucirumab Versus Docetaxel and Placebo in the Treatment of Stage IV Non–Small-Cell Lung Cancer After Disease Progression After 1 Previous Platinum-Based Therapy (REVEL): Treatment Rationale and Study Design
Garon, E. B., Cao, D., Alexandris, E., John, W. J., Yurasov, S., & Pérol, M. (2012) · Clinical Lung Cancer · doi:10.1016/j.cllc.2012.06.007 · Cited by 40
Self-citation
REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line treatment of stage IV non-small cell lung cancer (NSCLC) following disease progression after one prior platinum-based therapy.
Pérol, M., Ciuleanu, T., Arrieta, O. G., Prabhash, K., Syrigos, K. N., Göksel, T., Park, K., Kowalyszyn, R. D., Pikiel, J., Czyżewicz, G., et al. (2014) · Journal of Clinical Oncology · doi:10.1200/jco.2014.32.15_suppl.lba8006 · Cited by 17
Self-citation
A multicenter, double-blind, randomized phase III trial of ramucirumab plus docetaxel versus placebo plus docetaxel for treatment of Stage IV non-small cell lung cancer after disease progression on or after platinum-based therapy (REVEL): An Indian patient subgroup analysis
Prabhash, K., Doval, D. C., Rangarajan, B., Somani, N., Pruthi, A., Dyachkova, Y., & Puri, T. (2021) · Cancer Research Statistics and Treatment · doi:10.4103/crst.crst_159_21 · Cited by 3
Self-citation
A randomized, double-blind, phase II study of ramucirumab plus docetaxel vs placebo plus docetaxel in Japanese patients with stage IV non-small cell lung cancer after disease progression on platinum-based therapy
Yoh, K., Hosomi, Y., Kasahara, K., Yamada, K., Takahashi, T., Yamamoto, N., Nishio, M., Ohe, Y., Koue, T., Nakamura, T., et al. (2016) · Lung Cancer · doi:10.1016/j.lungcan.2016.07.019 · Cited by 110
Update of REVEL: A randomized, double-blind, phase III study of docetaxel (DOC) and ramucirumab (RAM; IMC-1121B) versus DOC and placebo (PL) in the second-line (2L) treatment of stage IV non-small cell lung cancer (NSCLC) including subgroup analysis of histology
Bidoli, P., Cappuzzo, F., Favaretto, A. G., Alabiso, O., Tiseo, M., Chella, A., Gebbia, V., Pizzuti, L., Paz-Ares, L. G., Pérol, M., et al. (2015) · Annals of Oncology · doi:10.1093/annonc/mdv343.04 · Cited by 2
Self-citation

See all

Authors: Garon, E. B., Ciuleanu, T.-E., Arrieta, O., Prabhash, K., Syrigos, K. N., Goksel, T., Park, K., Gorbunova, V., Kowalyszyn, R. D., Pikiel, J., Czyzewicz, G., Orlov, S. V., Lewanski, C. R., Thomas, M., Bidoli, P., Dakhil, S., Gans, S., Kim, J.-H., Grigorescu, A., Karaseva, N., Reck, M., Cappuzzo, F., Alexandris, E., Sashegyi, A., Yurasov, S., & Pérol, M.
Affiliations: University of California, Los Angeles (US)
Iuliu Hațieganu University of Medicine and Pharmacy (RO)
Instituto Nacional de Cancerología (MX)
Tata Memorial Hospital (IN)
Sotiria General Hospital (GR)
Samsung Medical Center (KR)
Russian Cancer Research Center NN Blokhin (RU)
Charing Cross Hospital (GB)
University Hospital Heidelberg (DE)
Azienda Ospedaliera San Gerardo (IT)
Cancer Center of Kansas (US)
Gemeinschaftskrankenhaus Herdecke (DE)
Yonsei University Health System (KR)
Institutul Oncologic Bucuresti (RO)
City Clinical Oncology Center (RU)
German Center for Lung Research (DE)
Ospedale di Livorno (IT)
Eli Lilly (United States) (US)
Corresponding author: Garon, Edward B
ORCID: Garon, Edward B
Ciuleanu, Tudor-Eliade
Arrieta, Oscar
Prabhash, Kumar
Park, Keunchil
Gorbunova, Vera
Pikiel, Joanna
Thomas, Michael
Dakhil, Shaker
Kim, Joo-Hang
Grigorescu, Alexandru
Reck, Martin
Cappuzzo, Federico
Sashegyi, Andreas
Yurasov, Sergey
Venue: The Lancet
Publisher: Elsevier BV
Published: 2014-08
Volume: 384
Issue: 9944
Pages: 665-673
ISSN: 0099-5355 (ISSN-L)
0140-6736
DOI: 10.1016/s0140-6736(14)60845-x
OpenAlex: W2140980839
Cited by: 1,309
References: 35
Citations by year: 2026: 57 · 2025: 71 · 2024: 116 · 2023: 102 · 2022: 110 · 2021: 97 · 2020: 108 · 2019: 102 · 2018: 106 · 2017: 148 · 2016: 155 · 2015: 115 · 2014: 19
FWCI: 116.89
Type: journal article
Language: en
Open access: green
www.sciencedirect.com
Licence: cc-by-nc-nd
www.elsevier.com/tdm/userlicense/1.0/ (tdm)
Locations: The Lancet (publishedVersion)
PubMed (publishedVersion)
BOA (University of Milano-Bicocca) (submittedVersion)
YUHSpace (Yonsei University Medical Library) (submittedVersion, cc-by-nc-nd)
Topics: Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Treatments and Mutations
Health Sciences › Medicine › Pulmonary and Respiratory Medicine › Lung Cancer Diagnosis and Treatment
Health Sciences › Medicine › Oncology › Lung Cancer Research Studies
Keywords: ramucirumab, docetaxel, non-small cell lung cancer, second-line therapy, VEGFR-2 inhibition, anti-angiogenic therapy, overall survival, progression-free survival, adverse events, drug safety, maintenance therapy, lung squamous cell carcinoma, non-squamous cell lung cancer
MeSH terms: Docetaxel, Ramucirumab, Adult, Aged, Antibodies, Monoclonal, Antineoplastic Combined Chemotherapy Protocols, Carcinoma, Non-Small-Cell Lung, Double-Blind Method, Female, Humans, Lung Neoplasms, Male, Middle Aged, Neoplasm Staging, Placebos, Platinum, Quality of Life, Survival Rate, Disease Progression, Taxoids, Antibodies, Monoclonal, Humanized

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Ramucirumab plus docetaxel versus placebo plus docetaxel for second-line treatment of stage IV non-small-cell lung cancer after disease progression on platinum-based therapy (REVEL): a multicentre, double-blind, randomised phase 3 trial

Abstract

Overview

Integrity signals

Verification

Claims the paper makes

Claims other papers make about this one

Citations

Cites

Cited by

Related

Metadata

Record

About these checks